Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: J Invest Dermatol. 2020 Feb 20;140(8):1609–1618.e7. doi: 10.1016/j.jid.2020.01.027

Table 3: Patients with discordant mutations between primary and metastatic tumors.

Twelve patients had discordant mutations between their primary and metastatic tumors. Mutations which were gained (a), or were undetected (b) in at least one of their metastatic tumors are displayed by patient. Specific details for each patient are displayed in Table 2.

a.
Discordance between Primary and Metastatic Tumors
Patient # Mutations Gained in Metastasis
03–036 BRAF
03–092 TERT -146
03–132 TERT -124
04–050 BRAF
04–168 TERT -124
06–001 NRAS
06–002 TERT -124
08–090 TERT -146, BRAF
b.
Discordance between Primary and Metastatic Tumors
Patient # Mutations Absent in Metastasis
04–050 TERT -124
04–111 TERT -124
05–137 TERT -146
06–001 BRAF
07–050 TERT -146
10–018 TERT -124,-146